These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 27414758)

  • 1. Protein-observed (19)F-NMR for fragment screening, affinity quantification and druggability assessment.
    Gee CT; Arntson KE; Urick AK; Mishra NK; Hawk LM; Wisniewski AJ; Pomerantz WC
    Nat Protoc; 2016 Aug; 11(8):1414-27. PubMed ID: 27414758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SAR by (Protein-Observed)
    Divakaran A; Kirberger SE; Pomerantz WCK
    Acc Chem Res; 2019 Dec; 52(12):3407-3418. PubMed ID: 31718149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fragment screening and druggability assessment for the CBP/p300 KIX domain through protein-observed 19F NMR spectroscopy.
    Gee CT; Koleski EJ; Pomerantz WC
    Angew Chem Int Ed Engl; 2015 Mar; 54(12):3735-9. PubMed ID: 25651535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorinated aromatic amino acids are sensitive 19F NMR probes for bromodomain-ligand interactions.
    Mishra NK; Urick AK; Ember SW; Schönbrunn E; Pomerantz WC
    ACS Chem Biol; 2014 Dec; 9(12):2755-60. PubMed ID: 25290579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Druggability indices for protein targets derived from NMR-based screening data.
    Hajduk PJ; Huth JR; Fesik SW
    J Med Chem; 2005 Apr; 48(7):2518-25. PubMed ID: 15801841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profiling the dynamic interfaces of fluorinated transcription complexes for ligand discovery and characterization.
    Pomerantz WC; Wang N; Lipinski AK; Wang R; Cierpicki T; Mapp AK
    ACS Chem Biol; 2012 Aug; 7(8):1345-50. PubMed ID: 22725662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Protein- and Ligand-Observed NMR Workflow to Screen Fragment Cocktails against Multiple Proteins: A Case Study Using Bromodomains.
    Johnson JA; Olson NM; Tooker MJ; Bur SK; Pomerantz WCK
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32872491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient affinity ranking of fluorinated ligands by
    Rüdisser SH; Goldberg N; Ebert MO; Kovacs H; Gossert AD
    J Biomol NMR; 2020 Nov; 74(10-11):579-594. PubMed ID: 32556806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of (19)F NMR Chemical Shifts in Labeled Proteins: Computational Protocol and Case Study.
    Isley WC; Urick AK; Pomerantz WC; Cramer CJ
    Mol Pharm; 2016 Jul; 13(7):2376-86. PubMed ID: 27218275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NMR screening in drug discovery.
    Moore JM
    Curr Opin Biotechnol; 1999 Feb; 10(1):54-8. PubMed ID: 10047510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NMR-based screening methods for lead discovery.
    Vogtherr M; Fiebig K
    EXS; 2003; (93):183-202. PubMed ID: 12613177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid Protein-Ligand Affinity Determination by Photoinduced Hyperpolarized NMR.
    Bütikofer M; Stadler GR; Kadavath H; Cadalbert R; Torres F; Riek R
    J Am Chem Soc; 2024 Jul; 146(26):17974-17985. PubMed ID: 38957136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein-Observed Fluorine NMR Is a Complementary Ligand Discovery Method to
    Urick AK; Calle LP; Espinosa JF; Hu H; Pomerantz WC
    ACS Chem Biol; 2016 Nov; 11(11):3154-3164. PubMed ID: 27627661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-field solution NMR spectroscopy as a tool for assessing protein interactions with small molecule ligands.
    Skinner AL; Laurence JS
    J Pharm Sci; 2008 Nov; 97(11):4670-95. PubMed ID: 18351634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current NMR Techniques for Structure-Based Drug Discovery.
    Sugiki T; Furuita K; Fujiwara T; Kojima C
    Molecules; 2018 Jan; 23(1):. PubMed ID: 29329228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications of NMR screening techniques to the pharmaceutical target Checkpoint kinase 1.
    Lancelot N; Piotto M; Theret I; Lesur B; Hennig P
    J Pharm Biomed Anal; 2014 May; 93():125-35. PubMed ID: 24280017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-Fluorotyrosine is a valuable but understudied amino acid for protein-observed
    Ycas PD; Wagner N; Olsen NM; Fu R; Pomerantz WCK
    J Biomol NMR; 2020 Jan; 74(1):61-69. PubMed ID: 31760571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Speeding-up the Determination of Protein-Ligand Affinities by STD NMR: The Reduced Data Set STD NMR Approach (rd-STD NMR).
    Rocha G; Ramírez-Cárdenas J; Padilla-Pérez MC; Walpole S; Nepravishta R; García-Moreno MI; Sánchez-Fernández EM; Ortiz Mellet C; Angulo J; Muñoz-García JC
    Anal Chem; 2024 Jan; 96(2):615-619. PubMed ID: 38165272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of site-specific binding and co-binding of ligands to macromolecules using 19F NMR.
    Jenkins BG
    Life Sci; 1991; 48(13):1227-40. PubMed ID: 2002752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein NMR-based screening in drug discovery.
    Zartler ER; Shapiro MJ
    Curr Pharm Des; 2006; 12(31):3963-72. PubMed ID: 17100607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.